Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition)

Bataller, 2005, Hepatic fibrosis, J Clin Invest, 115, 209, 10.1172/JCI24282 Fattovich, 2008, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors, J Hepatol, 48, 335, 10.1016/j.jhep.2007.11.011 Liaw, 2013, Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy, J Hepatol, 59, 880, 10.1016/j.jhep.2013.05.007 Xu LM. Attention to the treatment of liver fibrosis. Shi Jie Hua Ren Xiao Hua Za Zhi 2006; 14(17): 1649–53 [Chinese]. Xie YB, Xiao HM, Shi MJ, Chi CL. Progress in the treatment of liver fibrosis with traditional Chinese medicine. Shi Zhen Guo Yi Guo Yao 2016; 27(3): 703–6 [Chinese]. Ge XJ, Zhao CQ, Xu LM. Effect of Fuzheng Huayu Capsule on survival rate of patients with liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi 2017; 25(11):834–90 [Chinese with abstract in English]. Professional Committee of Liver Disease, Chinese Society of Integrated Traditional Chinese and Western Medicine. Guidelines for diagnosis and treatment of liver fibrosis with integrated traditional Chinese and Western medicine. Zhonghua Gan Zang Bing Za Zhi. 2006; 14(11): 866–70 [Chinese]. Deng T, Wang Y, Huang D, Zeng XT, Jin YH, Ren XQ, et al. Methodology for clinical practice guidelines—GRADE method theory. Zhongguo Xun Zheng Xin Xue Guan Yi Xue Za Zhi 2018; 10(12):1441–5, 1449 [Chinese with abstract in English]. Spengler, 2009, Hepatic microcirculation: a critical but neglected factor for the outcome of viral hepatitis, J Hepatol, 50, 631, 10.1016/j.jhep.2008.12.004 Muhanna, 2008, Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis, Hepatology, 48, 963, 10.1002/hep.22413 Shimoda, 2012, The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis, Clin Exp Immunol, 168, 279, 10.1111/j.1365-2249.2012.04581.x Trautwein, 2015, Hepatic fibrosis: concept to treatment, J Hepatol, 62, S15, 10.1016/j.jhep.2015.02.039 Hernandez-Gea, 2011, Pathogenesis of liver fibrosis, Annu Rev Pathol, 6, 425, 10.1146/annurev-pathol-011110-130246 Tan CY, Liu P. Theoretical origin of pathogenesis on accumulation due to deficiency of liver cirrhosis and clinical significance. Shanghai Zhong Yi Yao Da Xue Xue Bao 2010; 24(4): 25–8 [Chinese with abstract in English]. Mu YP, Liu CH, Zhang H, Liu P. Theory of “Asthenia and Deficiency Cause Accumulation” in liver cirrhosis——brief analysis on academic system of Professor Liu Ping. Shanghai Zhong Yi Yao Da Xue Xue Bao 2013; 27(2): 1–4 [Chinese with abstract in English]. Bedossa, 1996, An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group, Hepatology, 24, 289, 10.1002/hep.510240201 Knodell, 1981, Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis, Hepatology, 1, 431, 10.1002/hep.1840010511 Ishak, 1995, Histological grading and staging of chronic hepatitis, J Hepatol, 22, 696, 10.1016/0168-8278(95)80226-6 Scheuer, 2002, Scoring of chronic hepatitis, Clin Liver Dis, 6, 10.1016/S1089-3261(02)00009-0 Chevallier, 1994, A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies, Hepatology, 20, 349, 10.1002/hep.1840200213 Zheng YJ, Wang Y. Histological assessment of reversal of liver fibrosis and cirrhosis. Lin Chuang Gan Dan Bing Za Zhi 2019;35(4):709–13 [Chinese with abstract in English]. Liu TH. Serological assessment of the reversal of liver fibrosis and cirrhosis. Lin Chuang Gan Dan Bing Za Zhi 2019;35(04):714–9 [Chinese with abstract in English]. Chen YP, Liang XE. Radiological evaluation of the reversal of liver fibrosis and cirrhosis. Lin Chuang Gan Dan Bing Za Zhi 2019; 35(4):720–3 [Chinese with abstract in English]. Zhao WS, Xie W. Clinical assessment of the reversal of liver cirrhosis: “Point of return”. Lin Chuang Gan Dan Bing Za Zhi 2019; 35(4):724–7 [Chinese with abstract in English]. Zhang LJ, Zhang GC, Shen H, Hu M, Zhang JC. A cohort study on the reversal of patients with hepatitis B liver cirrhosis during the treatment of integrated Chinese and Western medicine. Hunan Shi Fan Da Xue Xue Bao Yi Xue Ban 2019; 16(1):34–8 [Chinese with abstract in English]. Sun YH, Hong Y. Advances in staging and treatment of hepatitis B cirrhosis. Lin Chuang Gan Zang Bing Za Zhi 2016; 32(6): 1036–9 [Chinese with abstract in English]. Kim, 2011, Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension, J Hepatol, 55, 1004, 10.1016/j.jhep.2011.02.012 Kim, 2012, The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis, J Hepatol, 57, 556, 10.1016/j.jhep.2012.04.029 Cheng DY, Wang XM, Ou WN, Sun L, Wang G, Ji SB, et al. Application of transient elastography in non-invasive diagnosis of liver fibrosis in nonviral liver disease. Zhongguo Gang Zang Bing Za Zhi Dian Zi Ban 2019;11(1):37–41 [Chinese with abstract in English]. Luo WP, Ma H, Wang Y. Advances in the application of transient elastography in noninvasive diagnosis of liver fibrosis. Lin Chuang Gan Dan Bing Za Zhi 2019; 35(3):635–9 [Chinese with abstract in English]. Cui AL, Wang JB, Xu LL, Tong MH. The effect of two-dimensional shear wave elastography and transient elastography in diagnosis of liver fibrosis in patients with chronic hepatitis B. Lin Chuang Chao Sheng Yi Xue Za Zhi 2018;20(12): 819–22 [Chinese with abstract in English]. Shen FF, Xu MY, Qu Y, Dong ZX, Cai XB, Wan XJ, et al. Diagnostic value of transient elastography for staging of liver fibrosis in patients with chronic liver disease: a meta-analysis. Wei Chang Bing Xue 2017; 22(4):218–23 [Chinese with abstract in English]. Yang W, Li Y, Yang YL. Research progress of transient elastic imaging (TE) in the diagnosis of liver fibrosis. Zhong Xi Yi Jie He Xin Xue Guan Bing Dian Zi Za Zhi 2018;6(9): 29–30, 32 [Chinese]. Ou XJ, Wang XM, Wu XN, Kong YY, Duan WJ, Zhou JL, et al. Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2015; 23(2): 103–6 [Chinese with abstract in English]. Yuan LC, Shao JH, Hao MN, Li C, Wang GP, Wang TL, et al. Correlation between liver hardness testing results obtained by FibroTouch and FibroScan and liver pathological stage. Zhonghua Gan Zang Bing Za Zhi 2014; 22(6): 425–9 [Chinese with abstract in English]. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63(1): 237–64. Kemp, 2015, Australian Liver Association (ALA). Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis, J Gastroenterol Hepatol, 30, 453, 10.1111/jgh.12865 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60(2):392–420. Sarri, 2013, Guideline Development Group. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance, BMJ, 346, 10.1136/bmj.f3893 Expert Committee on Consensus of Clinical Application of Transient Elastography. Expert consensus on clinical application of transient elastography (2015). Zhonghua Gan Zang Bing Za Zhi Dian Zi Ban. 2015; 7(2): 12–9 [Chinese]. Shen, 2019, Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis, Aliment Pharmacol Ther, 50, 93, 10.1111/apt.15298 Huwart, 2008, Magnetic resonance elastography for the noninvasive staging of liver fibrosis, Gastroenterology, 135, 32, 10.1053/j.gastro.2008.03.076 Yin, 2007, Assessment of hepatic fibrosis with magnetic resonance elastography, Clin Gastroenterol Hepatol, 5, 10.1016/j.cgh.2007.06.012 Faria, 2009, MR imaging of liver fibrosis: current state of the art, Radiographics, 29, 1615, 10.1148/rg.296095512 Lu LG, Cai XB. Interpretation of 2009 APASL Liver Fibrosis Consensus. Wei Chang Bing Xue. 2010; 15(06): 324–5 [Chinese]. Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346 Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178 Salkic, 2014, FibroTest/fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis, Am J Gastroenterol, 109, 796, 10.1038/ajg.2014.21 Zheng M, Cai WM, Weng HL, Liu RH. ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis. Zhonghua Chuan Ran Bing Za Zhi 2002; 20(4): 225–8 [Chinese with abstract in English]. Lin LJ, Xu LM. Whether there are credible diagnostic values for four serum markers of liver fibrosis. Gan Zang 2012; 17(6): 433–5 [Chinese]. Lin YH, Huang XQ, Pan AP, Pan YP, Chen J. Cluster analysis of related indicators of liver fibrosis. Guangxi Yi Ke Da Xue Xue Bao 2008; 25(5): 716–8 [Chinese]. Zhang ZL, Zhu CY. Application status of real-time shear wave elastography in liver. Zhonghua Yi Xue Chao Sheng Za Zhi Dian Zi Ban. 2014; 11(2): 108–10 [Chinese]. Barr, 2015, Elastography assessment of liver fibrosis: society of radiologists in ultrasound consensus conference statement, Radiology, 276, 845, 10.1148/radiol.2015150619 Zhu XC, Zhang CL, Zuo LS, Luo FC, Wang M. Clinic value of evaluation of hepatic fibrosis degree with acoustic radiation force impulse (ARFI). Zhonghua Quan Ke Yi Xue 2012; 10(1): 121–2 [Chinese with abstract in English]. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association; Hou JL, Lai W. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua Gan Zang Bing Za Zhi 2015; 23(12): 888–905 [Chinese]. Chinese Society of Hepatology, Chinese Medical Association, Wei L; Chinese Society of Infectious Diseases, Chinese Medical Association, Hou JL. The guideline of prevention and treatment for hepatitis C: a 2015 update. Zhonghua Gan Zang Bing Za Zhi 2015; 23(12): 906–23 [Chinese]. Society of Hepatology, Chinese Medical Association; Society of Digestive Diseases, Chinese Medical Association; Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis) (2015). Lin Chuang Gan Dan Bing Za Zhi 2015; 31(12): 1980–8 [Chinese]. Fatty Liver and Alcoholic Liver Disease Group, Society of Hepatology, Chinese Medical Association. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. Lin Chuang Gan Dan Bing Za Zhi 2010; 26(2): 120–6 [Chinese]. Fatty Liver and Alcoholic Liver Disease Group, Society of Hepatology, Chinese Medical Association. Guidelines for diagnosis and treatment of alcoholic liver disease. Lin Chuang Gan Dan Bing Za Zhi 2010; 26(3): 229–32 [Chinese]. Society of Hepatology, Chinese Medical Association; Society of Digestive Diseases, Chinese Medical Association; Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis (2015). Lin Chuang Gan Dan Bing Za Zhi 2016; 32(1): 9–22 [Chinese]. Lee, 2015, Pathobiology of liver fibrosis: a translational success story, Gut, 64, 830, 10.1136/gutjnl-2014-306842 Marcellin, 2013, Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, Lancet, 381, 468, 10.1016/S0140-6736(12)61425-1 Chang, 2010, Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B, Hepatology, 52, 886, 10.1002/hep.23785 Oze, 2014, Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy, Clin Gastroenterol Hepatol, 12, 1186, 10.1016/j.cgh.2013.11.033 Liu JX, Chen WM. Curative effect of INFα-2b combined with Fuzheng Huayu Capsule on chronic hepatitis B. Gan Zang 2012; 17(2): 140–2 [Chinese]. Tang LR, Guo T, Tao YY, Mu YP, Liu CH. A systematic review of combinative effects of Fuzheng Huayu capsule with nucleotide analogues on liver fibrosis due to chronic hepatitis B. Zhong Xi Yi Jie He Gan Bing Za Zhi 2013; 23(03): 183–7 [Chinese with abstract in English]. He J, Xu GL. Clinical efficacy of compound Biejia Ruangan tablets combined with adefovirdipivoxil in the treatment of hepatic fibrosis due to chronic hepatitis B: a systematic review. Zhongguo Yao Fang. 2010; 21(44): 4198–201 [Chinese with abstract in English]. Duan XL, Li GY, Li SM, Peng Y, Zhao TJ. Meta-analysis of influences of Fufang Biejia Ruangan Pian combined with entecavir on serum liver fibrosis markers of chronic hepatitis B. Zhongguo Yi Yuan Yao Xue Za Zhi 2015; 35(19): 1762–65 [Chinese with abstract in English]. Yuan JF, Jiang YA, Zhang CF, Hu KR, Zhang ZY. Therapeutic efficacy of antiviral drugs combined with Anluohuaxian Pill in treatment of hepatitis B-related cirrhosis: a meta-analysis. Chuan Ran Bing Xin Xi 2013; 26(5): 288–91 [Chinese with abstract in English]. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension. Lin Chuang Gan Dan Bing Za Zhi 2016; 31(2): 203–19 [Chinese]. Li L, He Q, Yang DG, Zhong BL, Zeng XM. Effectiveness and safety of Fuzheng Huayu Capsule for liver fibrosis of chronic hepatitis B: a systematic review. Zhongguo Xun Zheng Yi Xue Za Zhi 2008; 8(10): 892–7 [Chinese with abstract in English]. Lin W, Liu XJ, Wei N, Gao BX, Jiang GJ, Chang YQ. Systematic review of therapeutic effects of Fufang Biejia Ruangan Tablet on hepatic fibrosis. Wei Chang Bing Xue He Gan Bing Xue Za Zhi 2007; 16(1): 69–72 [Chinese with abstract in English]. Wang CX, Luo WS, Guo X, Kang Y. Systematic review of combinative effects of Anluo Huaxian Pills with nucleotide analogues on liver fibrosis due to chronic hepatitis B. Zhongguo Shi Yan Fang Ji Xue Za Zhi 2015; 21(7): 203–9 [Chinese with abstract in English]. Li GY, Li SM, Chen YX, PengY, Zhao TJ. Meta-analysis of Qianggan Capsule for serum liver fibrosis markers of chronic hepatitis. Liaoning Zhong Yi Za Zhi 2016; 43(5): 900–4 [Chinese with abstract in English]. Wang H, Yang LM, Huang L, Zhao YL, Chen DF. Clinical effects of Qianggan capsule on the liver tissue pathology and PDGF-BB, TGF-β1, TIMP-1, and MMP-1 factors in patients with chronic hepatitis B. Zhongguo Zhong Xi Yi Jie He Za Zhi 2011; 31(10): 1337–40 [Chinese with abstract in English]. Lu M, Mao H, Huang CZ, Tang YL, Zhang NY, Xi JD. Efficacy of compound embryonic bovine liver extract in patients with hepatitis B related liver cirrhosis. Shi Yong Gan Zang Bing Za Zhi 2015; 18(3): 262–5 [Chinese with abstract in English]. Zhu HJ, Hou YJ, Yuan KZ, Xu LM, Lin Z, Chen YP. Inhibitory effect of Anfate on expression of TGFβ1/Smad2 signaling pathway in treatment of hepatic fibrosis in mice. Lin Chuang Gan Dan Bing Za Zhi 2014; 30(4): 335–9 [Chinese with abstract in English]. Kang WW, Zhou L, Dang SS, Li HW, Chen Y, Duan ZP. Multicenter clinical study on the treatment of chronic hepatitis B with Ganshuang Granules. Zhonghua Zhong Yi Yao Za Zhi 2017;32(12):5689–93 [Chinese with abstract in English]. Xu Q, Zhu P, Zhang B, Du JX, Li F, Jiang SL. Clinical evaluation for effect of Rhubarb & Eupolyphage sinensis Pills on anti-fibrosis in liver. Shi Zhen Guo Yi Guo Yao 2011; 17(5): 808–9 [Chinese with abstract in English]. Yu P, Mao YQ, Zhu JJ. Clinical effect of pegylated interferon α-2a combined with Dahuang Zhechong Pill on patients with chronic hepatitis B-related hepatic fibrosis: a report of 65 cases. Suzhou Da Xue Xue Bao Yi Xue Ban 2011; 31(03): 486–7 [Chinese]. Chen RY, He SQ, Cheng Y, Li JL. Observation on curative effect of Biejia Decoction Pill on chronic hepatitis B hepatic fibrosis. Xin Zhong Yi 2011; 43(3): 34–5 [Chinese]. Chen J, Gu FH, Liu X, Dong WX. Protective effects of “Biejiajian Pill” on immunological hepatic fibrosis rats induced by pig serum. Shanghai Zhong Yi Yao Da Xue Xue Bao 2013; 27(1): 69–73 [Chinese with abstract in English]. Lee, 2011, Therapeutic effects of the oriental herbal medicine Sho-saiko-to on liver cirrhosis and carcinoma, Hepatol Res, 41, 825, 10.1111/j.1872-034X.2011.00829.x Chen, 2004, Sho-saiko-to prevents liver fibrosis induced by bile duct ligation in rats, Am J Chin Med, 32, 195, 10.1142/S0192415X04001862 Chen DD, Gong ZJ. Clinical effects of Xiaochaihu Decoction on chronic hepatitis B-related hepatic fibrosis. Xian Dai Zhong Xi Yi Jie He Za Zhi. 2011; 20(31): 3928–30 [Chinese]. Yin SS, Wang BE, Wang TL, Jia JD, Qian LX. The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial. Zhonghua Gan Zang Bing Za Zhi. 2004; 12(8): 31–4 [Chinese with abstract in English]. Cui HY, Gu WL, Ma YM, Liu P, Liu CH, Zhu BX, et al. The effects of Fugan decoction on hepatic fibrosis models in mouse and rat. Zhong Yao Yao Li Yu Lin Chuang 2012; 28(1): 137–141 [Chinese with abstract in English]. Friedman, 2006, Reversal of hepatic fibrosis—fact or fantasy?, Hepatology, 43, S82, 10.1002/hep.20974 Sun, 2017, New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment, Hepatology, 65, 1438, 10.1002/hep.29009 Lin LJ, Chen GF, Gu HT, Zhou Y, Yuan JL, Xing F, et al. Performance of FlbroScan in evaluating the curative effects of traditional Chinese medicine on liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2014; 22(2): 113–7 [Chinese with abstract in English].